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mir Lerman, MD*
ochester, Minnesota
bjectives The current study was designed to determine whether drug-eluting stents (DES) are su-
erior to bare-metal stents (BMS) in patients with stable angina.
ackground Percutaneous coronary intervention has been shown to decrease symptoms of angina;
ts use for stable angina has not been shown to reduce myocardial infarction or mortality.
ethods We conducted a retrospective, cross-sectional analysis of prospective data comparing the
se of BMS versus DES in patients who met criteria used by the COURAGE (Clinical Outcomes Utiliz-
ng Revascularization and Aggressive Drug Evaluation) study investigators. The primary outcome was
composite of death, myocardial infarction, stroke, and revascularization on follow-up.
esults The 1-year primary event rate was 15% in the DES group (95% conﬁdence interval [CI]:
1% to 18%), compared with 27% in the BMS group (95% CI: 23% to 31%, p  0.001). A Cox pro-
ortional hazard regression model was used to adjust for differences in patient characteristics and
howed a 1-year DES hazard ratio of 0.51 (95% CI: 0.36 to 0.71, p  0.001). After 1 year, event rates
or the primary outcome increased in DES subjects relative to BMS patients, such that longer fol-
ow-up analyses resulted in nonsigniﬁcant comparisons.
onclusions These results suggest that the use of DES for patients with stable coronary disease is
uperior to BMS for 1 year, but that the increment in beneﬁt decreased over continued follow-up.
urther research is necessary to identify additional factors to promote longer-term efﬁcacy and
afety of DES. (J Am Coll Cardiol Intv 2009;2:321–8) © 2009 by the American College of Cardiology
oundation
rom the *Division of Cardiovascular Diseases and the Center for Coronary Physiology and Imaging, and the †Division of
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322oronary heart disease is the leading cause of death in
merican men and women, accounting for 1 in 5 deaths in
004 (1). Use of percutaneous coronary intervention (PCI)
n the management of acute coronary syndromes has been
hown to decrease mortality and myocardial infarction (MI)
2–4). The use of PCI as part of standard management for
table coronary disease remains controversial, however.
ifestyle modification, including dietary changes, exercise,
nd smoking cessation along with proper control of blood
ressure, lipid profile, and diabetes is the guideline-based,
rst-line therapy for chronic stable angina (2,5). The use of
CI compared with medical therapy for stable coronary
isease has been shown to decrease angina and improve
hort-term exercise capacity (6–8) but has not been shown
o reduce mortality and risk of MI in prospective random-
zed trials (6–11). A number of limitations to these trials
xist, such as the enrollment of a relatively low-risk patient
opulation. In the initial studies, PCI consisted largely of
ngioplasty. A meta-analysis comparing angioplasty versus
are-metal stents (BMS) found no differences in death or MI
(12). Similarly, several pooled
analyses comparing the use of
drug-eluting stents (DES) versus
BMS for coronary artery disease
have shown no difference with
respect to death and MI (13–16).
In the COURAGE (Clinical
Outcomes Utilizing Revascular-
ization and Aggressive Drug
Evaluation) trial, the addition of
PCI to medical therapy resulted in
no overall reduction in death, MI,
or major cardiovascular outcomes
when compared with medical
herapy alone (17). However, DES were used in only 3% of
atients receiving PCI. The question remains whether the use
f DES may be beneficial. The current study was designed to
ddress the hypothesis that, in a population similar to that
tudied in the COURAGE trial, the use of DES reduces the
omposite outcome of death, nonfatal MI, revascularization,
nd stroke compared with BMS.
ethods
tudy design. We utilized a retrospective cross-sectional
nalysis of prospective data from the Mayo Clinic Rochester
oronary Catheterization Lab Registry, which includes
ollow-up data on death, MI, hospitalizations, cardiac
vents, and medication usage.
tudy population. Subject inclusion and exclusion criteria
irrored the protocol used by the COURAGE trial. Spe-
ifically, we started with all patients receiving BMS from
anuary 1, 1999, through March 31, 2003, and patients
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ABG  coronary artery
ypass grafting
I  confidence interval
ES  drug-eluting stent(s)
R  hazard ratio
QR  interquartile range
I  myocardial infarction
CI  percutaneous
oronary interventioneceiving DES from April 1, 2003, through March 31, c007, who had consented to allow use of their records for
esearch. Patients presenting with Canadian Cardiovascular
ociety class III or less angina were included. Patients were
xcluded if they presented with unstable angina, MI (within
days prior), cardiogenic shock or congestive heart failure,
f they had 50% stenosis of the left main artery with no
rior bypass, low ejection fraction (30% or 35% if
riple-vessel disease), PCI or coronary artery bypass grafting
CABG) within the last 6 months, a history of cardiac
ransplant, or cardiac arrest with ongoing cardiopulmonary
esuscitation. In total, 874 stents were placed in 872 unique
atients (Fig. 1). Within the BMS and DES groups, only
he first qualifying PCI per patient was used for analysis.
reatment. In addition to the intervention, all patients
ndergoing PCI were seen in the Cardiovascular Health
linic as part of their medical management. Data on
edical management is recorded in Table 1.
linical outcome. The primary outcome measure was the
Figure 1. Selection Process
Flow chart depicting selection process of individuals studied. BMS  bare-
metal stent(s); CABG  coronary artery bypass grafting; CHF  congestive
heart failure; DES  drug-eluting stent(s); EF  ejection fraction; IABP 
intra-aortic balloon pump; LM  left main artery; MI  myocardial infarc-
tion; PCI  percutaneous coronary intervention; CCS  Canadian Cardio-
vascular Society.omposite rate of death, nonfatal MI, revascularization, and
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323troke during follow-up after PCI. Secondary outcomes
ncluded the individual outcomes from the primary end
oint, composites of death and MI, death and stroke, death
nd cardiac hospitalization, as well as severe angina. Suc-
essful PCI was defined as post-procedural stenosis 20%
n at least 1 treated lesion and no in-hospital death, Q-wave
I, or CABG. MI was defined as the presence of 2 of the
ollowing: prolonged chest pain (20 min), enzyme eleva-
ion 2 normal limit, ST-segment T-wave changes or
ew Q waves on serial electrocardiograms indicative of
yocardial damage. Severe angina was defined as Canadian
ardiovascular Society class III or greater. Cardiac hospi-
alization was defined as meeting 1 of the following:
ospitalization for unstable angina, MI, angiogram, CABG,
ny PCI (balloon, atherectomy, laser, stent, and thrombec-
omy), congestive heart failure, arrhythmia, heart transplant,
r other cardiac surgery.
ollow-up. Database information regarding medication us-
ge, symptoms, and hospitalizations was obtained via tele-
hone. Patients were contacted at 6 month intervals for 12
onths and yearly thereafter. This information, as well as
ecords from other hospitals, was reviewed and entered in
he database.
tatistical analysis. Continuous data are summarized as
Table 1. Clinical Characteristics
Variable
Age, yrs
Male gender, n (%)
Canadian Cardiovascular Society class, n (%)
I
II
III
History of CHF, n (%)
Diabetes, n (%)
Hypertension, n (%)
Body mass index, kg/m2
History of cholesterol 240, n (%)
Smoking status, n (%)
Never
Former
Current
History of MI (7 days), n (%)
Prior PCI, n (%)
Prior CABG, n (%)
Peripheral vascular disease, n (%)
CVA/TIA, n (%)
Moderate/severe renal disease, n (%)
Plusorminus values aremeanSD, except those from theCOURAGE (C
study data, which are median SD.
CABG  coronary artery bypass grafting; CHF  congestive heart
myocardial infarction; PCI percutaneous intervention; TIA transieean  SD, except where noted. Discrete data are pre- 1ented as frequency (group percentage). Differences between
roups were compared using Student t test, Pearson’s
hi-square test, and the Mann-Whitney rank sum test for
ontinuous, nominal, and ordinal data, respectively. Kaplan-
eier estimates were used to describe survival rates on
ollow-up after PCI, with the log-rank test employed to test
roup differences. Cox proportional hazards models were
sed to estimate adjusted hazards ratios for the DES effect
djusted for risk factors that differed significantly between
he 2 groups. Schoenfeld residual plots were inspected to
ssess the plausibility of the proportional hazards assump-
ion. When the assumption appeared to be violated, a
ikelihood ratio test comparing models with and without
eparate effects was conducted to determine the significance
f the violation. The choice of follow-up time at which to
odel the divergence of effects was determined by visual
nspection of the Schoenfeld plot for a range of potential
utpoints, followed by estimating the likelihood functions
or models of various cutpoints.
esults
aseline patient characteristics. We studied a total of 474
atients treated with BMS from the period of January 1,
DES
474)
DES Use
(n  400) p Value
10.5 66.0 10.5 0.34
(72%) 291 (72%) 0.91
0.001
(2%) 11 (3%)
(53%) 290 (72%)
(45%) 103 (25%)
(4%) 14 (4%) 0.91
(24%) 128 (32%) 0.015
(77%) 311 (80%) 0.28
 5.5 29.6 5.4 0.58
(85%) 332 (86%) 0.74
0.11
(40%) 180 (46%)
(50%) 168 (43%)
(10%) 41 (11%)
(30%) 86 (22%) 0.009
(25%) 140 (35%) 0.002
(22%) 94 (23%) 0.67
(10%) 36 (9%) 0.62
(11%) 33 (8%) 0.19
(1%) 3 (1%) 0.88
utcomesUtilizingRevascularization andAggressiveDrugEvaluation)
CVA  cerebrovascular accident; DES  drug-eluting stent(s); MI 
mic attack.No
(n 
66.7
346
10
253
215
17
116
358
29.4
385
188
235
49
139
121
106
47
51
4
linicalO
failure;999, through March 31, 2003, and 400 patients receiving
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324ES from April 1, 2003, through March 31, 2007. The
aseline characteristics of both groups are found in Table 2,
ith angiographic comparisons in Table 3. Mean age was
6.6 10.5 years for BMS recipients and 66.0 10.5 years
or DES patients. Seventy-two percent of both groups were
ale patients. Seventy-four percent of BMS patients and
5% of the DES patients had multivessel disease. Forty-five
ercent of BMS patients and 25% of the DES patients in
ur study had Canadian Cardiovascular Society class III
ngina. Overall, 65% of the BMS and 83% of the DES
nderwent entirely elective procedures. Eighty percent of the
atients receiving BMS received 1 stent, and 81% of those with
ES received 1 stent. Success rate, defined as post-procedural
tenosis of less than or equal to 20% and no in-hospital death,
-wave MI, or CABG, was 99% for both groups.
Table 2. Angiographic Characteristics
Variable
No
(n 
Multivessel disease (70/50),* n (%) 336
Worst lesion type, n (%)
A 14
B1 99
B2 176
C 177
Maximum device size (mm) 3.4
Maximum balloon length (mm) 16.9
Urgency of PCI, n (%)
Elective 309
Urgent 165
Number of segments treated 1.6
Total vessels treated, n (%)
1 381
2 78
3 15
Vein graft intervention, n (%) 39
Success rate,† n (%) 467
*Defined as 2 lesions greater than 70%and50%;†defined as20%pos
myocardial infarction, or coronary artery bypass grafting.
Abbreviations as in Table 1.
Table 3. Medication Use at Year 1
Variable
N
(n
Medication use evaluated at 1 year* 38
Aspirin use at 1 year 35
Beta-blocker use at 1 year 27
Calcium-channel blocker use at 1 year 9
ACE inhibitor use at 1 year 17
Lipid-lowering use at 1 year 32
NTG use at 1 year 15
Plavix use at 1 year 4
Values are n (%). *Data collected between 9 and 18 months after procACE angiotensin-converting enzyme; DES drug-eluting stent(s); NTGedication and treatment targets. Follow-up medication
ata at 1 year was available in 81% of BMS and 84% of the
ES group (Table 1). At year 1, angiotensin-converting
nzyme inhibitors were used in 45% of the BMS group
ersus 56% in the DES group (p 0.001). However, we did
ot have data on angiotensin receptor blockers, which may
ccount for some of this difference. Another difference at
ear 1 was the use of lipid-lowering agents, as 83% of the
MS group versus 69% of DES patients (p  0.001), were
sing these agents. Follow-up data on total cholesterol,
igh-density lipoprotein, low-density lipoprotein, triglycer-
des, and body mass index was not available in our registry.
lavix (Bristol-Myers Squibb Co., New York, New York;
nd Sanofi-aventis, Bridgewater, New Jersey) use at year 1
n the BMS group was 10% and 38% for the DES group.
DES Use
(n400) p Value
233 (65%) 0.010
0.035
7 (2%)
78 (20%)
127 (32%)
180 (46%)
3.2 0.4 0.001
14.8 4.0 0.001
0.001
333 (83%)
67 (17%)
1.6 0.8 0.38
0.69
325 (81%)
67 (17%)
8 (2%)
11 (3%) 0.001
397 (99%) 0.31
dure stenosis andno in-hospitalmyocardial infarction, death, Q-wave
)
DES Use
(n  400) p Value
) 335 (84%) 0.37
) 317 (95%) 0.10
) 255 (76%) 0.16
) 64 (19%) 0.06
) 189 (56%) 0.001
) 233 (70%) 0.001
) 120 (36%) 0.16
) 133 (40%) 0.001DES
474)
(74%)
(3%)
(21%)
(38%)
(38%)
 0.6
 5.2
(65%)
(35%)
 0.8
(80%)
(16%)
(3%)
(8%)
(99%)
t-proceo DES
 474
6 (81%
3 (91%
6 (72%
6 (25%
2 (45%
0 (83%
8 (41%
0 (10%
edure.nitroglycerine.
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325ollow-up period. The median (interquartile range [IQR])
ollow-up in the DES group was 33.7 months (IQR: 23.5 to
4.5) compared with 44.4 months (IQR: 28.8 to 57.3) in
he BMS group (p  0.001).
rimary outcomes. To adjust for differences in patient
haracteristics, a Cox proportional hazards regression model
as used. Diagnostic plots indicated that the proportional
azards assumption (i.e., that the DES effect was constant
ver follow-up) did not fit the data for several end points,
amely the composite of death, MI, stroke, and revascular-
zation, as well as for MI, revascularization, severe angina,
nd the composite end point of death and MI. The
iagnostics indicated a change in DES effect direction and
agnitude around 9 months. The proportional hazards
ssumption appeared to hold for other end points. The
odels accounting for a different effect after 6, 7, 8, 9, 10,
1, and 12 months were computed to assess the best time at
hich to model the change in DES effect. For various end
oints, the highest model likelihoods were typically at 11
onths, sometimes 10 months. In all cases, a cutpoint at 12
onths yielded a better fitting model than a cutpoint at 9
onths, so we rounded up from 11 to 12 months for the
hoice of cutoff.
The primary outcome, a composite of death, nonfatal MI,
evascularization, and stroke, had a 3-year event rate of 34%
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Figure 2. Kaplan-Meier Plots
Three-year outcomes of death/MI/revascularization/stroke, death/MI, death, ann the DES group (95% confidence interval [CI]: 28% to D9%) compared with 39% in the BMS group (95% CI: 34%
o 44%, p  0.057) (Fig. 2). Based on the multivariable
odel, patients treated with DES were at significantly lower
isk of events than BMS patients during the first 12 months
fter PCI (hazard ratio [HR]: 0.51, 95% CI: 0.36 to 0.71, p
0.001) (Table 4). After 12 months, there was a trend
oward increased event rates among DES patients compared
ith BMS patients (HR: 1.36, 95% CI: 0.94 to 1.96, p 
.10).
econdary outcomes. The 3-year event rate for the individ-
al outcome of death showed no statistical difference be-
ween DES 7% (95% CI: 4% to 9%) and BMS 7% (95% CI:
% to 9%, p  0.75) (Fig. 2). The 3-year event rate of MI
as significantly lower in the DES group, 8% (95% CI: 5%
o 11%) versus the BMS group, 13% (95% CI: 9% to 16%,
 0.028). The Cox proportional hazards regression model
howed that at 12 months, DES patients were at signifi-
antly lower risk for MI (HR: 0.43, 95% CI: 0.24 to 0.78,
 0.005). After 1 year, DES patients were at higher risk
or MI (HR: 2.39, 95% CI: 0.99 to 5.78, p  0.053) (Table
). The secondary composite end point of death and MI had
trend toward benefit with DES; the 3-year event DES rate
as 14% (95% CI: 10% to 18%) versus BMS 17% (95% CI:
4% to 21%, p  0.10) (Fig. 2). The Cox proportional
azards regression model showed that patients treated with
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326eath and MI during the first 12 months after PCI (HR:
.42, 95% CI: 0.25 to 0.73, p  0.002). After 12 months,
here was a nonsignificant trend toward increased events in
he DES group (HR: 1.63, 95% CI: 0.96 to 2.78, p 
.072). Revascularization, after correction with the Cox
roportional hazards regression model, showed an advan-
age at 1 year for DES use (HR: 0.50, 95% CI: 0.34 to 0.74,
 0.001) but increased risk at 3 years (HR: 1.60, 95% CI:
.03 to 2.50, p  0.039). Severe angina showed a trend
oward benefit with DES at 3 years and after correction with
he Cox proportional hazards regression model; this benefit
ersisted for 1 year (HR: 0.61, 95% CI: 0.41 to 0.89, p 
.011) but showed a nonsignificant association afterward
HR: 1.16, 95% CI: 0.77 to 1.76, p  0.41). The other
ndividual secondary outcomes of stroke, composites of
eath and stroke, as well as death and cardiac hospitalization
Table 4. Outcomes
End Point
Kaplan-Meier Event %
(95% CI)
DES BMS
Death/MI/revascularization/
CVA
12 months 15 (11–8) 27 (23–31
3 yrs 34 (28–39) 39 (34–44
Death
12 months 0.8 (0.0–1.7) 1.5 (0.4–2.
3 yrs 7 (4–9) 7 (4–9)
MI
12 months 4 (2–6) 11 (8–14)
3 yrs 8 (5–11) 13 (9–16)
Revascularization
12 months 11 (8–14) 20 (16–23
3 yrs 26 (21–30) 28 (24–32
CVA
12 months 0.3 (0.0–0.8) 1.1 (0.1–2.
3 yrs 0.8 (0.0–1.9) 2.1 (0.7–3.
Death/MI
12 months 5 (3–7) 12 (9–15)
3 yrs 14 (10–18) 17 (14–21
Death/CVA
12 months 1.0 (0.0–2.0) 2.6 (1.1–4.
3 yrs 7 (4–10) 8 (6–11)
Death/cardiac hospitalization
12 months 13 (10–17) 17 (13–20
3 yrs 33 (28–39) 34 (29–38
Severe angina
12 months 11 (8–14) 19 (16–23
3 yrs 24 (19–30) 30 (25–34
*Where 2 hazard ratios (HRs) are presented, the first is the effect for the
no differential effect before and after 12 months, then only 1 HR is giv
BMS bare metal stent(s); CI confidence interval; other abbreviahowed no significant differences (Table 4). yiscussion
his study compared the use of DES and BMS for the
reatment of stable angina, as defined by the COURAGE
rial entry criteria. After correcting for differences in patient
haracteristics, our primary end point, the composite of
eath, MI, cerebrovascular accident, and revascularization,
howed a statistically significant reduction in events with use
f DES compared with BMS at 1 year. The secondary end
oint of MI also had a statistically significant reduction in
vents with DES during this time period. Both effects
ersisted for 1 year, after which such patients were found to
e at higher risk. These results were driven mostly by lower
I rates in the first 12 months after PCI. Adjusted HRs for
he end points of death/MI, revascularization, and severe
ngina also showed statistically significant decreased risk 1
Log-Rank p Value Adjusted HR (95% CI); p Value*
0.057
0.51 (0.36–0.71);0.001
1.36 (0.94–1.96); 0.10
0.75 0.94 (0.51–1.73); 0.84
0.028
0.43 (0.24–0.78); 0.005
2.39 (0.99–5.78); 0.053
0.26
0.50 (0.34–0.74);0.001
1.60 (1.03–2.50); 0.039
0.14 0.85 (0.21–3.53); 0.82
0.10
0.42 (0.25–0.73); 0.002
1.63 (0.96–2.78); 0.072
0.38 0.95 (0.54–1.66); 0.85
0.72 0.95 (0.73–1.24); 0.72
0.067
0.61 (0.41–0.89); 0.011
1.16 (0.77–1.76); 0.48
months, the second is the effect after the first 12months. If there was
mmarize the overall follow-up effect.
in Table 1.)
)
6)
)
)
0)
5)
)
1)
)
)
)
)
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327emaining secondary end points of death, stroke, and the
omposites of death and stroke, and death and cardiac
ospitalization had associations that did not reach statistical
ignificance.
The primary end point, depicted in Figure 2, showed an
dvantage for DES, particularly during the early portion of
he follow-up period. The Cox proportional hazard regres-
ion model showed that this benefit existed for 12 months.
his may be explained by differences in medical therapy.
irst, this finding may be a result of cessation of dual
ntiplatelet therapy in the DES group. The registry data
howed that there was no difference in the use of aspirin at
ear 1 in both groups. At year 1, however, the use of
lopidogrel in the DES group was only 38%. Given the risk
or late stent thrombosis, current guidelines recommend
reatment with clopidogrel after placement of DES for 1
ear (18). A recent study supports the concept of a clopi-
ogrel rebound effect, as both groups of patients in this
tudy—whether being treated with clopidogrel plus optimal
edical therapy or clopidogrel plus PCI after acute coronary
yndrome — had increased 90-day mortality after stopping
he clopidogrel (19). In addition, in the current study, there
as a significant difference in the use of statins at year 1,
ith 83% of the BMS and only 69% of the DES group on
tatins at this time. Collection of data regarding medication
se was obtained via telephone at 9, 12, or 18 months and
s subject to some degree of error; there is unlikely to be such
large difference in medication compliance in these groups.
his discrepancy may also account for some of the loss of
linical significance near year 1.
The secondary end point of death showed no statistical
ifference between DES and BMS, but the adjusted com-
osite end point of death and MI showed a significant
enefit with DES at 1 year. The COURAGE trial, as well
s a meta-analysis of over 18,000 patients by Stettler et al.
20), did not show any statistically significant benefit in
educing the composite of death and MI with use of PCI
17). The study of Stettler et al. (20), however, did show a
rend toward lower death rates in sirolimus-eluting stents.
n addition, Shishehbor et al. (21) showed that overall
ortality was reduced in patients receiving DES versus
MS after 4 years of follow-up. Previous studies have
howed reductions in death up to 3 years; Mauri et al. (22)
howed that DES provided a reduction in mortality after 2
ears, and Tu et al. (23) showed that DES reduced death up
o 3 years.
In the current study, the composite of death and MI was
argely driven by the reduction in MI during the first 12
onths after DES and, like the primary end point, dis-
layed a trend toward increased rates after 12 months.
iscontinuation of clopidogrel may help explain this find-
ng. A study of Swedish patients receiving BMS and
ES—for any indication—reported a trend toward lowervent rates for the composite of death and MI over the first cmonths after implantation of DES, with increasing rates
fterward (14). The authors attributed this observation to an
ncrease in late stent thrombosis and noted that most
atients were taking clopidogrel for a maximum of 6
onths. The finding of early reduction of death and MI in
atients receiving DES followed by clopidogrel discontin-
ation and subsequent increased rates of events at 6 to 18
onths has also been shown in an observational study (24).
he current study’s findings encourage further research to
dentify factors that may extend the protective period and
itigate risk.
A recent study comparing BMS and DES for off-label
se showed decreased rates of repeat revascularization at 1
ear for patients receiving DES (25). After adjusting for
ifferences in patient characteristics risk factors, we also
bserved significantly less revascularizations in the DES
roup in the first 12 months after DES. However, there was
statistically significant increased risk of revascularization at
years.
tudy limitations. This study is a nonrandomized, retro-
pective cross-sectional analysis of prospective data and has
he inherent limitations of such a study. The 2 groups
tudied were from different time periods; thus, procedure
ate is confounded with treatment group. Selection of the 2
eriods was used to increase sample size, as BMS-only cases
atching inclusion criteria represented only 12% of DES
ases during the DES era. This small sample size precluded
direct comparison between these groups during the DES
ra. In addition, we included 23 of 400 patients in the DES
roup who also had a BMS placed. This represents less than
% of the DES group. We included a small percentage of
atients whose procedure was classified as urgent, which
ay indicate a small increase in patient risk profile for a
mall subset of patients in this study. Follow-up at 1 year
as completed in 96.2% of BMS and 89.5% of DES
atients. One reason for this is that some patients may have
een contacted slightly before 12 months; the 10 months
ollow-up rate is 93% in DES patients. The other reason is
hat, if after multiple attempts the patient was not reached
y telephone, further attempts were deferred until the next
cheduled call 12 months later. Medication use was evalu-
ted at year 1 in 84% of the DES patients and 81% of the
MS group. The lower rate for medication follow-up may
e due to patients discussing their hospitalizations and/or
ymptoms, but declining to take further time to additionally
iscuss medication use during follow-up phone calls. We
ere also limited in follow-up data regarding body mass
ndex and cholesterol levels.
onclusions
he current study demonstrated that DES for stable angina
ere shown to have a statistically significant reduction in theomposite of death, MI, stroke, and revascularization com-
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328ared with BMS for the first year after stent placement.
his was largely driven by decreased rates of MI and
evascularization. However, at 3 years, event rates for the
rimary outcome increased for DES patients but resulted in
nonsignificant comparison, while the secondary outcome
f revascularization showed statistically significant increase
n events for DES subjects. These results suggest that the
se of DES for patients with stable angina is superior to
MS for 1 year, but that the increment in benefit decreased
ver continued follow-up. Further research is necessary to
dentify additional factors to promote longer-term efficacy
nd safety of DES.
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